Vitamin D Guidelines: New Research & Recommendations
- New clinical practice guidelines issued in June 2024 by the Endocrine Society have stirred controversy regarding vitamin D supplementation and testing.
- Michael Holick, a professor at Boston University Chobanian & Avedisian school of Medicine, recently compared these 2024 guidelines with those he helped develop in 2011.
- Holick expressed concern that the new guidelines, which focus on the general healthy population and skeletal health benefits of vitamin D, could create confusion.
Dive into the heart of the vitamin D debate! Recent guidelines are shaking up the landscape of vitamin D supplementation with major shifts in testing and recommendations. This article dissects the controversy, focusing on the conflicting advice from leading experts like Dr. Michael Holick, who challenges the new approach to vitamin D and its role in health. Explore the implications of the new guidelines advising against routine vitamin D testing for healthy individuals,especially considering the needs of at-risk populations and infants. News Directory 3 provides a comprehensive analysis of the latest research, contrasting it with previous recommendations and highlighting the potential benefits of vitamin D in fighting disease. Discover what’s next as we look into the future of vitamin D guidelines research.
Vitamin D Guidelines Spark Debate Among Experts: A Closer look
Updated June 18, 2025
New clinical practice guidelines issued in June 2024 by the Endocrine Society have stirred controversy regarding vitamin D supplementation and testing. the guidelines advise against routine 25-hydroxyvitamin D testing in healthy individuals and suggest limiting supplementation beyond the daily recommended intake to specific risk groups. This approach to vitamin D and its role in disease prevention has prompted discussion among medical professionals.
Dr. Michael Holick, a professor at Boston University Chobanian & Avedisian school of Medicine, recently compared these 2024 guidelines with those he helped develop in 2011. His analysis appears in the journal Endocrine Practice.
Holick expressed concern that the new guidelines, which focus on the general healthy population and skeletal health benefits of vitamin D, could create confusion. He believes it will be difficult for health care professionals to determine if patients at risk for vitamin D deficiency are,in fact,deficient,since routine screening is not recommended.
One key difference, according to Holick, is that the 2011 guidelines offered guidance on when to evaluate a patient’s vitamin D status, while the 2024 version does not. The earlier guidelines also provided details on the appropriate amount of vitamin D needed to treat and prevent deficiency across all age groups. The new guidelines only address supplementation for those one year and older, omitting recommendations for younger infants.
While the 2024 guidelines acknowledge that a higher daily intake of 2,500 ius of vitamin D might reduce the risk of adverse birth outcomes,they do not recommend monitoring vitamin D status in pregnant women or increasing intake above the standard 600 ius daily.
Holick contends that the 2024 guidelines relied heavily on randomized controlled trials, many of which were not placebo-controlled, and disregarded numerous association studies. He argues that this approach overlooks the potential benefits of vitamin D in reducing cancer mortality, autoimmune disorders, the progression of prediabetes to type 2 diabetes, and respiratory tract infections.
He further stated that vitamin D could reduce COVID-19 infection, hospitalizations, and mortality, and accelerate the time it takes for COVID-positive patients to test negative. Holick also pointed to studies suggesting that vitamin D could lower the risk of preterm birth and preeclampsia.
What’s next
The debate surrounding these differing guidelines highlights the ongoing need for research and discussion regarding the optimal role of vitamin D in maintaining health and preventing disease. Further studies may help clarify the appropriate levels of supplementation and testing for various populations.